Download CRIMSON brochure

Resources and sources of evidence

Other Information for people with RRMS, their friends and family

Medically approved information about DMTs for people with RRMS

  1. Betaferon 250 microgram/ml, powder and solvent for solution for injection. Summary of Product Characteristics - Updated 03 December 2018
  2. Medicines and Healthcare Products Regulatory Agency. Dimethyl fumarate (Tecfidera): Updated advice on risk of progressive multifocal leukoencephalopathy - Updated 18 April 2016.
  3. Tecfidera 120mg and 240mg gastro-resistant hard capsules. Summary of Product Characteristics - Updated 18 January 2019.
  4. Copaxone 20mg/ml, solution for injection, Pre-Filled Syringe. Summary of Product Characteristics - Updated 10 Jan 2019.
  5. Aubagio 14mg film-coated tablets. Summary of Product Characteristics - Updated 27 March 2019.
  6. Mavenclad 10 mg tablets. Summary of Product Characteristics - Updated 8 August 2018.
  7. OCREVUS 300 mg concentrate for solution for infusion - Updated 25 January 2018.
  8. Lemtrada 12 mg concentrate for solution for infusion. Summary of Product Characteristics - Updated 15 January 2019.
  9. European Medicines Agency. Lemtrada Annex I Summary of product characteristics - Updated 15 January 2019.
  10. Gilenya 0.25mg and 0.5mg hard capsules. Summary of Product Characteristics - Updated 9 April 2019.
  11. Tysabri 300 mg concentrate for solution for infusion. Summary of Product Characteristics - Updated 31 May 2017.

Medical sources for RRMS and DMTs

  1. Baker D, Marta M, Pryce G, et al, Memory B cells are major targets for effective immunotherapy in Relapsing Remitting Multiple Sclerosis. EBioMedicine. 2017; 16: 41-50.
  2. Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014; 83:1022-1024.
  3. Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Practical Neurology. 2019. 19:106-114.
  4. Eskyte I, Manzano A, Pepper G, et al. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis. Multiple Sclerosis and Related Disorders, 2019. 27: 370-377.
  5. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related disorders, 2016. 9: S5-S48.
  6. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology, 2014. 83:278-286.
  7. Mackenzie IS, Morant SV, Bloomfield GA, et al. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. Journal Neurology Neurosurgery Psychiatry 2014. 85:76-84.
  8. National Institute for Care and Health Excellence (NICE). Managing Multiple Sclerosis NICE Pathway - Updated 29 January 2019.
  9. National Institute for Care and Health Excellence (NICE). Multiple Sclerosis Quality Standard - Updated 14 January 2016.
  10. National Institute for Care and Health Excellence (NICE). Disease-modifying therapies for multiple sclerosis. NICE Pathway - Updated 29 January 2019
  11. NHS England. Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies. NHS England Reference: 170079ALG. Gateway reference: 07603 - Updated 8 March 2019.
  12. Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: Revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology, 2015. 15:273-279.
  13. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 2018. 17:162-173.
  14. Rae-Grant, A., Day, G.S., Marrie, R.A., et al, 2018. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90(17), pp.789-800.
  15. Lucchetta R, Tonin FS, Borba HHL, et al. Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis. 2018. CNS Drugs. 32:813-826
  16. Webb EJ, Meads D, Eskyte I, et al. A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. The Patient-Patient-Centered Outcomes Research. 2018.

Patient decision aid sources

  1. Bekker H, Thornton JG, Airey CM, et al. Informed decision making: an annotated bibliography and systematic review. UK: Health Technology Assessment Number. 1999. 3. NHS R&D.
  2. Bekker HL, Winterbottom A, Gavaruzzi T, et al. The dialysis decision aid booklet: making the right choices for you - Updated Sept 2017. Kidney Research UK: Peterborough, UK.
  3. Elwyn G, O’Connor A, Stacey D, et al. International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006. 26:417.
  4. Sepucha K, Abhyankar P, Hoffman A, et al. Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist. BMJ Qual Saf 2018; 27:380-388.
  5. O’Connor, Stacey, Jacobsen. Ottawa Personal Decision Guide. (2015). Ottawa Hospital Research Institute & University of Ottawa, Canada.
  6. Ferron Parayre A, Labrecque M, Rousseau M, et al. Validation of SURE, a four-item clinical checklist for detecting decisional conflict in patients. Med. Dec. Mak. 2014. 34:54-62.